Ardena cements growth and expansion with new HQ

12 Nov 2018

Larger headquarters will enable the company to free up space for additional laboratories and further expand capabilities.

CDMO Ardena has cemented a sustained period of growth with a move to expanded headquarters in Gent, Belgium.

Ardena cements growth and expansion with new HQ

Since 2015, Ardena has grown from 40 to 250 staff members and seen more than 20% organic growth per year, fueled by the CDMO’s M&A strategy which has seen four acquisitions in the past 2 years, most recently Netherlands-based ChemConnection and Sweden-based Syntagon.

It now operates across six sites in Belgium, the Netherlands, Sweden and Latvia and boasts a global reach, servicing more than 300 customers in Europe, the US, Japan and Korea.

Ardena offers integrated drug development services encompassing drug substance and drug product development, clinical manufacturing, clinical logistics, full product analytical and bioanalytical support and regulatory dossier development. The company is also a leader in nanomedicine technology.

Harry Christiaens, CEO at Ardena said: “After several acquisitions and an ongoing growth period, we are firmly on track to reach our €35 million sales target for 2018 as part of our wider strategy to become a leading integrated drug development company.

“This new, larger headquarters will enable us to free up space for additional laboratories at our other sites and further expand our capabilities. It will also provide a base for our staff training centre to ensure we develop our team.

“As we move into 2019, we look forward to continued international success and carrying on with our acquisition strategy to further strengthen our service offering.”

Ardena was formed in 2017, following the merging of three companies with complementary drug development capabilities: Pharmavize in Belgium, and Crystallics and Analytical Biochemical Laboratory (ABL) in the Netherlands.

Read More

Related news

Leaf Expression Systems launches first line of Hypertrans research products

Leaf Expression Systems launches first line of Hypertrans research products

13 Jun 2019

Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins.

Read more 
Clinical supply milestone reached for triple-negative breast cancer treatment

Clinical supply milestone reached for triple-negative breast cancer treatment

12 Jun 2019

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.

Read more 
Combining IT and OT software to solve manufacturing’s most frequent challenges

Combining IT and OT software to solve manufacturing’s most frequent challenges

11 Jun 2019

PTC and Rockwell Automation combine technologies to accelerate customers’ digital transformation initiatives.

Read more 
Sphere Fluidics secures funding to support its single cell analysis system

Sphere Fluidics secures funding to support its single cell analysis system

11 Jun 2019

Funding will also be used to further expand operations in the UK and US.

Read more 
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

6 Jun 2019

Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.

Read more 
Cambrex completes new process and analytical development facility at Sweden manufacturing site

Cambrex completes new process and analytical development facility at Sweden manufacturing site

5 Jun 2019

The process technology laboratories will include new capabilities in the scaling up of potent molecules requiring containment.

Read more 
Sterling pilot plant facility expansion up and running

Sterling pilot plant facility expansion up and running

4 Jun 2019

Additional three new reactor trains will help the CDMO to meet growing market demand for smaller API batch sizes.

Read more 
Lilly gets its hands on non-opioid pain asset

Lilly gets its hands on non-opioid pain asset

4 Jun 2019

Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.

Read more 
Updated clinical trial simulation software saves time and money

Updated clinical trial simulation software saves time and money

3 Jun 2019

One customer saves $25m and 3 years' development time in their clinical development strategy.

Read more 
Ampersand Capital Partners to acquire Vibalogics

Ampersand Capital Partners to acquire Vibalogics

3 Jun 2019

Vibalogics will expand capabilities to meet rapidly growing demand for development and manufacturing of complex viral products.

Read more